HTG Molecular Diagnostics, Inc. (HTGM): Price and Financial Metrics

HTG Molecular Diagnostics, Inc. (HTGM): $0.54

0.29 (+117.57%)

POWR Rating

Component Grades














  • HTGM scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.3% of US stocks.
  • HTGM's strongest trending metric is Growth; it's been moving up over the last 99 days.
  • HTGM ranks lowest in Stability; there it ranks in the 1st percentile.

HTGM Stock Summary

  • With a market capitalization of $3,038,736, HTG MOLECULAR DIAGNOSTICS INC has a greater market value than merely 0.29% of US stocks.
  • With a year-over-year growth in debt of -49.27%, HTG MOLECULAR DIAGNOSTICS INC's debt growth rate surpasses merely 5.57% of about US stocks.
  • The volatility of HTG MOLECULAR DIAGNOSTICS INC's share price is greater than that of 93.39% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to HTG MOLECULAR DIAGNOSTICS INC are SCYX, SOFO, IRBT, BKYI, and WPRT.
  • Visit HTGM's SEC page to see the company's official filings. To visit the company's web site, go to

HTGM Valuation Summary

  • In comparison to the median Healthcare stock, HTGM's EV/EBIT ratio is 103.7% lower, now standing at -0.3.
  • Over the past 92 months, HTGM's price/sales ratio has gone down 27.3.

Below are key valuation metrics over time for HTGM.

Stock Date P/S P/B P/E EV/EBIT
HTGM 2022-12-05 0.5 2.7 -0.1 -0.3
HTGM 2022-12-02 0.5 2.9 -0.2 -0.3
HTGM 2022-12-01 0.5 2.9 -0.2 -0.3
HTGM 2022-11-30 0.5 3.0 -0.2 -0.3
HTGM 2022-11-29 0.6 3.6 -0.2 -0.3
HTGM 2022-11-28 0.7 4.1 -0.2 -0.4

HTGM Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -20.36%.
  • The 5 year revenue growth rate now stands at 255.1%.
  • The 4 year net income to common stockholders growth rate now stands at 25.56%.
Over the past 52 months, HTGM's revenue has gone down $13,893,077.

The table below shows HTGM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.803983 -19.7746 -22.09316
2022-06-30 8.073514 -19.39548 -22.06764
2022-03-31 8.656136 -18.09486 -18.79438
2021-12-31 8.906828 -16.50855 -17.14517
2021-09-30 8.612758 -16.66869 -16.24386
2021-06-30 7.869446 -16.81077 -17.16503

HTGM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HTGM has a Quality Grade of C, ranking ahead of 33.06% of graded US stocks.
  • HTGM's asset turnover comes in at 0.216 -- ranking 65th of 75 Measuring and Control Equipment stocks.
  • SMIT, BIO, and AATC are the stocks whose asset turnover ratios are most correlated with HTGM.

The table below shows HTGM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.216 0.523 -0.726
2021-03-31 0.210 0.515 -0.879
2020-12-31 0.223 0.533 -0.795
2020-09-30 0.264 0.596 -0.676
2020-06-30 0.325 0.559 -0.705
2020-03-31 0.421 0.568 -0.690

HTGM Price Target

For more insight on analysts targets of HTGM, see our HTGM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.75 Average Broker Recommendation 1.5 (Moderate Buy)

HTGM Stock Price Chart Interactive Chart >

Price chart for HTGM

HTGM Price/Volume Stats

Current price $0.54 52-week high $5.68
Prev. close $0.25 52-week low $0.20
Day low $0.25 Volume 45,437,700
Day high $0.75 Avg. volume 1,394,346
50-day MA $0.50 Dividend yield N/A
200-day MA $0.92 Market Cap 5.97M

HTG Molecular Diagnostics, Inc. (HTGM) Company Bio

HTG Molecular Diagnostics, Inc. develops and markets technology platforms that facilitate the routine use of complex molecular profiling. The company’s HTG Edge and HTG EdgeSeq platforms consist of instrumentation, consumables, and software analytics that are used in molecular profiling applications, including tumor profiling, biomarker development and prospectively, and molecular diagnostic testing. The company was founded in 1997 and is based in Tucson, Arizona.

HTGM Latest News Stream

Event/Time News Detail
Loading, please wait...

HTGM Latest Social Stream

Loading social stream, please wait...

View Full HTGM Social Stream

Latest HTGM News From Around the Web

Below are the latest news stories about HTG MOLECULAR DIAGNOSTICS INC that investors may wish to consider to help them evaluate HTGM as an investment opportunity.

HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences

TUCSON, Ariz., Dec. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced there will be at least eight scientific abstracts featuring HTG’s proprietary HTG EdgeSeq™ technology presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS 2022) and at the 64th Annual American Society of Hematolog

Yahoo | December 6, 2022

HTG Molecular GAAP EPS of -$0.41 beats by $0.13, revenue of $1.25M misses by $1.58M

  • HTG Molecular press release (NASDAQ:HTGM): Q3 GAAP EPS of -$0.41 beats by $0.13.
  • Revenue of $1.25M (-50.4% Y/Y) misses by $1.58M.

Seeking Alpha | November 11, 2022

H.C. Wainwright Reaffirms Their Buy Rating on HTG Molecular Diagnostics (HTGM)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics (HTGM - Research Report) today and set a price target of $2.00. The company's shares opened today at $0.52.According to TipRanks, Chen is an analyst with an average return of -28.8% and a 23.31% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $1.50, which is a 190.47% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $1.00 price target.

Carrie Williams on TipRanks | November 11, 2022

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q3 Loss, Misses Revenue Estimates

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 21.15% and 44.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

HTG Molecular Diagnostics Reports Third Quarter 2022 Results

TUCSON, Ariz., Nov. 10, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today reported financial results for the quarter ended September 30, 2022 and provided recent business highlights. “We are delighted with the continued and rapid progress we have made this past quarter in our effort to reposition HTG as a platform-

Yahoo | November 10, 2022

Read More 'HTGM' Stories Here

HTGM Price Returns

1-mo 8.02%
3-mo -26.14%
6-mo 8.00%
1-year -87.11%
3-year -94.46%
5-year -98.05%
YTD -90.04%
2021 13.15%
2020 -54.50%
2019 -72.37%
2018 25.12%
2017 -9.38%

Continue Researching HTGM

Here are a few links from around the web to help you further your research on Htg Molecular Diagnostics Inc's stock as an investment opportunity:

Htg Molecular Diagnostics Inc (HTGM) Stock Price | Nasdaq
Htg Molecular Diagnostics Inc (HTGM) Stock Quote, History and News - Yahoo Finance
Htg Molecular Diagnostics Inc (HTGM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.807 seconds.